Base de dados : MEDLINE
Pesquisa : D13.444.154 [Categoria DeCS]
Referências encontradas : 9 [refinar]
Mostrando: 1 .. 9   no formato [Detalhado]

página 1 de 1

  1 / 9 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370268
[Au] Autor:Haller N; Helmig S; Taenny P; Petry J; Schmidt S; Simon P
[Ad] Endereço:Department of Sports Medicine, Rehabilitation and Prevention, Johannes Gutenberg-University of Mainz, Mainz, Germany.
[Ti] Título:Circulating, cell-free DNA as a marker for exercise load in intermittent sports.
[So] Source:PLoS One;13(1):e0191915, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Attempts to establish a biomarker reflecting individual player load in intermittent sports such as football have failed so far. Increases in circulating DNA (cfDNA) have been demonstrated in various endurance sports settings. While it has been proposed that cfDNA could be a suitable marker for player load in intermittent sports, the effects on cfDNA of repeated sprinting as an essential feature in intermittent sports are unknown. For the first time, we assessed both alterations of cfDNA due to repeated maximal sprints and due to a professional football game. METHODS: Nine participants were subjected to a standardised sprint training session with cross-over design of five maximal sprints of 40 meters with either "short" (1 minute) or "long" pauses (5 minutes). Capillary cfDNA and lactate were measured after every sprint and venous cfDNA before and after each series of sprints. Moreover, capillary cfDNA and lactate values were taken in 23 professional football players before and after incremental exercise testing, during the course of a training week at rest (baseline) and in all 17 enrolled players following a season game. RESULTS: Lactate and venous cfDNA increased more pronounced during "short" compared to "long" (1.4-fold, p = 0.032 and 1.7-fold, p = 0.016) and cfDNA correlated significantly with lactate (r = 0.69; p<0.001). Incremental exercise testing increased cfDNA 7.0-fold (p<0.001). The season game increased cfDNA 22.7-fold (p<0.0001), while lactate showed a 2.0-fold (p = 0.09) increase compared to baseline. Fold-changes in cfDNA correlated with distance covered during game (spearman's r = 0.87, p = 0.0012), while no correlation between lactate and the tracking data could be found. DISCUSSION: We show for the first time that cfDNA could be an objective marker for distance covered in elite intermittent sports. In contrast to the potential of more established blood-based markers like IL-6, CK, or CRP, cfDNA shows by far the strongest fold-change and a high correlation with a particular load related aspect in professional football.
[Mh] Termos MeSH primário: Biomarcadores/metabolismo
Ácidos Nucleicos Livres/metabolismo
Exercício
Esportes
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cell-Free Nucleic Acids)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191915


  2 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460452
[Au] Autor:Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
[Ad] Endereço:State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, China.
[Ti] Título:Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
[So] Source:Oncotarget;8(16):26625-26636, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to systematically evaluate the diagnostic value of cell free DNA (cfDNA) for breast cancer. RESULTS: Among 308 candidate articles, 25 with relevant diagnostic screening qualified for final analysis. The mean sensitivity, specificity and area under the curve (AUC) of SROC plots for 24 studies that distinguished breast cancer patients from healthy controls were 0.70, 0.87, and 0.9314, yielding a DOR of 32.31. When analyzed in subgroups, the 14 quantitative studies produced sensitivity, specificity, AUC, and a DOR of 0.78, 0.83, 0.9116, and 24.40. The 10 qualitative studies produced 0.50, 0.98, 0.9919, and 68.45. For 8 studies that distinguished malignant breast cancer from benign diseases, the specificity, sensitivity, AUC and DOR were 0.75, 0.79, 0.8213, and 9.49. No covariate factors had a significant correlation with relative DOR. Deek's funnel plots indicated an absence of publication bias. MATERIALS AND METHODS: Databases were searched for studies involving the use of cfDNA to diagnose breast cancer. The studies were analyzed to determine sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and the summary receiver operating characteristic (SROC). Covariates were evaluated for effect on relative DOR. Deek's Funnel plots were generated to measure publication bias. CONCLUSIONS: Our analysis suggests a promising diagnostic potential of using cfDNA for breast cancer screening, but this diagnostic method is not yet independently sufficient. Further work refining qualitative cfDNA assays will improve the correct diagnosis of breast cancers.
[Mh] Termos MeSH primário: Biomarcadores Tumorais
Neoplasias da Mama/diagnóstico
Neoplasias da Mama/genética
Ácidos Nucleicos Livres
DNA de Neoplasias
[Mh] Termos MeSH secundário: Área Sob a Curva
Neoplasias da Mama/sangue
Bases de Dados Genéticas
Detecção Precoce de Câncer/métodos
Feminino
Seres Humanos
Biópsia Líquida
Viés de Publicação
Curva ROC
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Cell-Free Nucleic Acids); 0 (DNA, Neoplasm)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15775


  3 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454691
[Au] Autor:Conka J; Konecná B; Lauková L; Vlková B; Celec P
[Ad] Endereço:Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
[Ti] Título:Fetal DNA does not induce preeclampsia-like symptoms when delivered in late pregnancy in the mouse.
[So] Source:Placenta;52:100-105, 2017 Apr.
[Is] ISSN:1532-3102
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The etiology of preeclampsia is unclear. Fetal DNA is present in higher concentrations in the plasma of pregnant women suffering from preeclampsia than in the plasma of healthy pregnant women. A previously published study has shown that human fetal DNA injected into pregnant mice induces preeclampsia-like symptoms when administered between gestation days 10-14. The aim of our experiment was to determine whether or not similar effects would be induced by administration of human and mouse fetal DNA, as well as mouse adult DNA and lipopolysaccharide during late pregnancy in the mouse. METHODS: Experimental animals were injected daily intraperitoneally during gestation days 14-18 with either saline - negative control, lipopolysaccharide - positive control, or various types of DNA. On gestation day 19, blood pressure and proteinuria were measured, and placental and fetal weights were recorded. RESULTS: Fetal and placental hypotrophy were induced only by lipopolysaccharide (p < 0.001). Neither fetal nor adult DNA induced changes in fetal/placental weight. None of the experimental groups had higher blood pressure or urinary protein in comparison to saline treated animals. DISCUSSION: In our experiment, we found that there was no effect from intraperitoneally injected human fetal DNA, mouse fetal DNA, or mouse adult DNA on pregnant mice. Additionally, relatively high doses of various types of DNA did not induce preeclampsia-like symptoms in mice when administered in late pregnancy. Our negative results support the hypothesis that the increase of fetal DNA circulating in maternal circulation during the third trimester is rather a consequence than a cause of preeclampsia.
[Mh] Termos MeSH primário: Pressão Sanguínea/fisiologia
Ácidos Nucleicos Livres/administração & dosagem
Placenta/fisiopatologia
Pré-Eclâmpsia/etiologia
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Feminino
Lipopolissacarídeos
Camundongos
Pré-Eclâmpsia/fisiopatologia
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell-Free Nucleic Acids); 0 (Lipopolysaccharides)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  4 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29484962
[Au] Autor:Kumar M; Choudhury Y; Ghosh SK; Mondal R
[Ad] Endereço:1 Department of Biotechnology, Assam University, Silchar, India.
[Ti] Título:Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics.
[So] Source:Tumour Biol;40(2):1010428318760342, 2018 Feb.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The conventional method of measuring biomarkers in malignant tissue samples has already given subversive growth in cancer diagnosis, prognosis, and therapy selection. However, the regression and heterogeneity associated with tumor tissue biopsy have urged for the development of an alternative approach. Considering the limitations, cell-free DNA has emerged as a surrogate alternative, facilitating preoperative chemoradiotherapy (p < 0.0001) treatment response in rectal cancer and detection of biomarker in lung cancer. This potential of cell-free DNA in several other cancers has yet to be explored based on clinical relevance by optimizing the preanalytical factors. This review has highlighted the crucial parameters from blood collection to cell-free DNA analysis that has a significant impact on the accuracy and reliability of clinical data. The quantity of cell-free DNA is also a limiting factor. Therefore, a proper preanalytical factor for blood collection, its stability, centrifugation speed, and plasma storage condition are to be optimized for developing cancer-specific biomarkers useful for clinical purpose. Liquid biopsy-based origin of cell-free DNA has revolutionized the area of cancer research. Lack of preanalytical and analytical procedures may be considered for identification of novel biomarkers through next-generation sequencing of tumor-originated cell-free DNA in contradiction to tissue biopsy for cancer-specific biomarkers.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Ácidos Nucleicos Livres/genética
DNA de Neoplasias/genética
Mutação
Neoplasias/genética
[Mh] Termos MeSH secundário: Genômica
Sequenciamento de Nucleotídeos em Larga Escala/métodos
Seres Humanos
Neoplasias/diagnóstico
Neoplasias/terapia
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Cell-Free Nucleic Acids); 0 (DNA, Neoplasm)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180228
[St] Status:MEDLINE
[do] DOI:10.1177/1010428318760342


  5 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464939
[Au] Autor:Rykova E; Sizikov A; Roggenbuck D; Antonenko O; Bryzgalov L; Morozkin E; Skvortsova K; Vlassov V; Laktionov P; Kozlov V
[Ad] Endereço:Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.
[Ti] Título:Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.
[So] Source:Arthritis Res Ther;19(1):85, 2017 May 02.
[Is] ISSN:1478-6362
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Early diagnosis of rheumatoid arthritis (RA) is crucial to providing effective therapy and often hampered by unspecific clinical manifestations. Elevated levels of extracellular circulating DNA (cirDNA) in patients with autoimmune disease were found to be associated with etiopathogenesis. To our knowledge, this is the first study to investigate the putative diagnostic use of cirDNA in RA and its association with disease activity. METHODS: Blood samples were taken from 63 healthy subjects (HS) and 74 patients with RA. cirDNA was extracted from plasma and cell surface-bound cirDNA fractions (csbDNA). cirDNA concentration was measured by quantitative real-time polymerase chain reaction. Rheumatoid factor was analyzed by immunonephelometry, whereas C-reactive protein and anticitrullinated protein/peptide antibodies (ACPA) were detected by enzyme-linked immunosorbent assay. RESULTS: Plasma cirDNA was significantly elevated in patients with RA compared with HS (12.0 versus 8.4 ng/ml, p < 0.01). In contrast, nuclear csbDNA (n-csbDNA) was significantly decreased (24.0 versus 50.8 ng/ml, p < 0.01), whereas mitochondrial csbDNA (m-csbDNA) was elevated (1.44 × 10 copies/ml versus 0.58 × 10 copies/ml, p < 0.05) in RA. The combination of csbDNA (mitochondrial + nuclear) with ACPA reveals the best positive/negative likelihood ratios (LRs) for the discrimination RA from HS (LR+ 61.00, LR- 0.03) in contrast to ACPA (LR+ 9.00, LR- 0.19) or csbDNA (LR+ 8.00, LR- 0.18) alone. CONCLUSIONS: Nuclear and mitochondrial cirDNA levels in plasma and on the surface of blood cells are modulated in RA. Combination of cirDNA values with ACPA can improve the serological diagnosis of RA.
[Mh] Termos MeSH primário: Artrite Reumatoide/sangue
Artrite Reumatoide/diagnóstico
Ácidos Nucleicos Livres/sangue
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Autoanticorpos/sangue
Biomarcadores/sangue
Estudos de Coortes
Diagnóstico Precoce
Feminino
Seres Humanos
Masculino
Meia-Idade
Análise de Componente Principal
Distribuição Aleatória
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers); 0 (Cell-Free Nucleic Acids)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s13075-017-1295-z


  6 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29417678
[Au] Autor:Dabi Y; Costa JM; Benachi A
[Ad] Endereço:Department of Obstetrics and Gynecology, Antoine Beclere Hospital, 92140, Clamart, France.
[Ti] Título:Re: Low-molecular-weight heparin associated with reduced fetal fraction and subsequent false- negative cell-free DNA test result for trisomy 21.
[So] Source:Ultrasound Obstet Gynecol;51(2):278, 2018 02.
[Is] ISSN:1469-0705
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome de Down
Heparina de Baixo Peso Molecular
[Mh] Termos MeSH secundário: Ácidos Nucleicos Livres
Cromossomos Humanos Par 13
Cromossomos Humanos Par 18
Seres Humanos
Diagnóstico Pré-Natal
Trissomia
Síndrome da Trissomia do Cromossomo 13
Síndrome da Trissomía do Cromossomo 18
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Cell-Free Nucleic Acids); 0 (Heparin, Low-Molecular-Weight)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1002/uog.18984


  7 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468865
[Au] Autor:Husain H; Nykin D; Bui N; Quan D; Gomez G; Woodward B; Venkatapathy S; Duttagupta R; Fung E; Lippman SM; Kurzrock R
[Ad] Endereço:Division of Hematology and Oncology, University of California San Diego, San Diego, California. hhusain@ucsd.edu.
[Ti] Título:Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
[So] Source:Mol Cancer Ther;16(5):948-955, 2017 May.
[Is] ISSN:1538-8514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Collection of cell-free DNA (cfDNA) from the blood of individuals with cancer has permitted noninvasive tumor genome analysis. Detection and characterization of cfDNA in ascites and pleural effusions have not yet been reported. Herein, we analyzed cfDNA in the ascites and pleural effusions from six individuals with metastatic cancer. In all cases, cfDNA copy number variations (CNV) were discovered within the effusate. One individual had a relevant alteration with a high copy amplification in in a never smoker with lung cancer, who showed only and amplification in a prior tissue biopsy. Another subject with metastatic breast cancer had cytology-positive ascites and an activating mutation identified in the tissue, blood, and ascites collectively. This individual had tumor regression after the administration of the mTOR inhibitor everolimus and had evidence of chromotripsis from chromosomal rearrangements noted in the cell-free ascitic fluid. These results indicate that cfDNA from ascites and pleural effusions may provide additional information not detected with tumor and plasma cell-free DNA molecular characterization, and a context for important insights into tumor biology and clonal dynamic change within primary tumor and metastatic deposits. .
[Mh] Termos MeSH primário: Ascite/genética
Ácidos Nucleicos Livres/genética
Genoma Humano/genética
Neoplasias/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Ascite/sangue
Linhagem Celular Tumoral
Ácidos Nucleicos Livres/sangue
Classe I de Fosfatidilinositol 3-Quinases/genética
Quinase 4 Dependente de Ciclina/genética
Variações do Número de Cópias de DNA/genética
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação
Neoplasias/sangue
Neoplasias/classificação
Neoplasias/patologia
Derrame Pleural/genética
Proteínas Proto-Oncogênicas c-mdm2/genética
Receptor do Fator de Crescimento Epidérmico/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell-Free Nucleic Acids); EC 2.3.2.27 (MDM2 protein, human); EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2); EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases); EC 2.7.1.137 (PIK3CA protein, human); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); EC 2.7.11.22 (CDK4 protein, human); EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1158/1535-7163.MCT-16-0436


  8 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448961
[Au] Autor:Divya KP; Dharuman V
[Ad] Endereço:Molecular Electronics Laboratory, Department of Bioelectronics and Biosensors, Science Campus, Alagappa University, Karaikudi 630003, India.
[Ti] Título:Supported binary liposome vesicle-gold nanoparticle for enhanced label free DNA and protein sensing.
[So] Source:Biosens Bioelectron;95:168-173, 2017 Sep 15.
[Is] ISSN:1873-4235
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Supported binary liposome mixture of cationic liposome N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium propane (DOTAP) and the zwitterionic liposome 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) were tethered on thiol monolayers in the absence and presence of gold nanoparticle to enhance sensor stability and sensitivity for label free DNA and protein sensing for the first time. Cysteamine hydrochloride (Cyst), 3-Mercaptopropionic acid (MPA), 11-Mercaptoundecanoic acid (MUDA) and 11-amino-1-undecane thiol (AUT) monolayers were used as tethers on gold surfaces. Electrochemical studies in the presence of [Fe(CN) ] indicate that the presence of both DOPE and AuNP decreases the electrostatic interaction between DOTAP and MPA layer during the formation of DOPE-DOTAP-AuNP (DDA) whereas they enhance the repulsive force on the Cyst and AUT monolayers. In the thiol monolayer supported DDA, the gelation of neutral lipid DOPE by the AuNP is disfavored which inturn promotes stability of vesicle structure. The membrane protein melittin's interaction with the DDA indicates the presence of intact vesicle by showing decreased charge transfer for the MUDA and AUT in the presence of [Fe(CN) ] . On the contrary, the presence of the bilayer and semi circled DDA on the MPA and cysteamine layers were confirmed by the increased redox reaction. Atomic Force Microscopic (AFM) and Transmission Electron Microscopic (TEM) images support the presence of an array like semi circled DDA on the MPA and well separated DDA vesicles on the MUDA with variable sizes. Dynamic Light Scattering (DLS) and Fourier Transform Infrared spectroscopy (FTIR) suggest effective coordination between DOPE, DOTAP and AuNP. Label free DNA hybridization sensing in presence of the negatively charged [Fe(CN) ] indicates the lowest DNA detection limit of 1×10 M with linearity range 1×10 to 1×10 M. Similarly, streptavidin sensing shows the lowest detection of 1ngml with a linear range 100ng to 1µg due to the increased reactive sites and distance.
[Mh] Termos MeSH primário: Técnicas Biossensoriais
Ácidos Nucleicos Livres/isolamento & purificação
Lipossomos/química
Proteínas/isolamento & purificação
[Mh] Termos MeSH secundário: Ácido 3-Mercaptopropiônico
Ácidos Nucleicos Livres/química
Cisteamina/química
Ácidos Graxos Monoinsaturados/química
Ouro/química
Limite de Detecção
Lipídeos/química
Nanopartículas Metálicas/química
Microscopia de Força Atômica
Microscopia Eletrônica de Transmissão
Hibridização de Ácido Nucleico
Fosfatidiletanolaminas/química
Compostos de Amônio Quaternário/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell-Free Nucleic Acids); 0 (Fatty Acids, Monounsaturated); 0 (Lipids); 0 (Liposomes); 0 (Phosphatidylethanolamines); 0 (Proteins); 0 (Quaternary Ammonium Compounds); 2462-63-7 (dioleoyl phosphatidylethanolamine); 5UX2SD1KE2 (Cysteamine); 7440-57-5 (Gold); B03TJ3QU9M (3-Mercaptopropionic Acid); MR86K0XRQP (1,2-dioleoyloxy-3-(trimethylammonium)propane)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE


  9 / 9 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29261771
[Au] Autor:Naumann DN; Hazeldine J; Dinsdale RJ; Bishop JR; Midwinter MJ; Harrison P; Hutchings SD; Lord JM
[Ad] Endereço:Academic Department of Military Surgery and Trauma, Royal Centre for Defence Medicine, Queen Elizabeth Hospital, Birmingham, United Kingdom.
[Ti] Título:Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: A prospective observational study.
[So] Source:PLoS One;12(12):e0189870, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cell free deoxyribonucleic acid (cfDNA) has been proposed as a biomarker of secondary complications following trauma. Raised thrombomodulin and syndecan-1 levels have been used to indicate endotheliopathy, and are associated with inflammation, coagulopathy, and mortality. The current study aimed to analyse the association between cfDNA and biomarkers of endotheliopathy in a cohort of trauma patients, and whether raised levels of cfDNA were associated with poorer clinical outcomes. METHODS: Serum thrombomodulin and syndecan-1 were used as biomarkers of endotheliopathy and compared to plasma cfDNA in trauma patients from two prospective longitudinal observational studies. Cohort A (n = 105) had a predicted injury severity score (ISS) >8, and had blood sampled within 1h of injury and at 4-12h. Cohort B (n = 17) had evidence of haemorrhagic shock, and had blood sampled at a median time of 3.5h after injury. Relationships between biomarkers were tested using multivariable linear regression models that included the covariates of gender, age, ISS, Glasgow Coma Scale, lactate, systolic blood pressure, and heart rate. A model was fitted to investigate whether changes in cfDNA were associated with similar changes in endothelial biomarkers. RESULTS: The mean age was 41 (SD 19), and the median ISS was 25 (IQR 12-34). There was a significant association between cfDNA levels and both syndecan-1 and thrombomodulin levels (both p<0.001). This was independent of all covariates except for ISS, which significantly correlated with cfDNA levels. 50 ng/ml change in syndecan-1 and 1 ng/ml change in thrombomodulin corresponded to 15% and 20% increases in cfDNA levels respectively (both p<0.001). Patients who died had significantly higher prehospital and in-hospital cfDNA levels (both p<0.05). CONCLUSIONS: Raised cfDNA levels are associated with markers of endotheliopathy following trauma, and are associated with mortality. This relationship is present within the first hour of injury, and a change in one biomarker level is reflected by similar changes in the others. These findings are in keeping with the hypothesis that circulating DNA and endothelial injury share a common pathway following trauma.
[Mh] Termos MeSH primário: Ácidos Nucleicos Livres/sangue
Endotélio Vascular/patologia
Ferimentos e Lesões/sangue
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Transtornos da Coagulação Sanguínea/sangue
Transfusão de Sangue
Feminino
Seres Humanos
Tempo de Internação
Masculino
Estudos Prospectivos
Sindecana-1/sangue
Trombomodulina/metabolismo
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cell-Free Nucleic Acids); 0 (Syndecan-1); 0 (THBD protein, human); 0 (Thrombomodulin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189870



página 1 de 1
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde